VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion (Q39797640)

14 September 2017

VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion (English)

1 reference

14 September 2017

1 reference

Feng-qiang Wang

1

1 reference

14 September 2017

Elaine Barfield

2

1 reference

14 September 2017

Sonia Dutta

3

1 reference

14 September 2017

Tarah Pua

4

1 reference

14 September 2017

David A Fishman

5

1 reference

14 September 2017

language of work or name

English

0 references

publication date

18 September 2009

1 reference

14 September 2017

1 reference

14 September 2017

115

1 reference

14 September 2017

3

1 reference

14 September 2017

414-423

1 reference

Angiogenesis as a strategic target for ovarian cancer therapy

14 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

VEGF, VEGFR-1, VEGFR-2, microvessel density and endothelial cell proliferation in tumours of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Vascular endothelial growth factor (VEGF) receptor neuropilin-1's distribution in astrocytic tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Neuropilin-1 is differentially expressed in myoepithelial cells and vascular smooth muscle cells in preneoplastic and neoplastic human breast: a possible marker for the progression of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Vascular endothelial growth factor modulates skeletal myoblast function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Selective adapter recruitment and differential signaling networks by VEGF vs. shear stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

SU1498, an inhibitor of vascular endothelial growth factor receptor 2, causes accumulation of phosphorylated ERK kinases and inhibits their activity in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Functional VEGF and VEGF receptors are expressed in human medulloblastomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Neuropilins in neoplasms: expression, regulation, and function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

The role of neuropilins in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Lysophospholipids activate ovarian and breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.019

10.1016/J.YGYNO.2009.08.019

7 January 2021

Identifiers

DOI

1 reference

14 September 2017

1 reference